Generic Name and Formulations:
Crotalidae polyvalent immune Fab (Ovine) 1g/vial; lyophilized pwd for IV infusion after reconstitution and dilution; contains thimerosal.
Indications for CROFAB:
To manage patients with minimal or moderate North American crotalid (eg, rattlesnakes, copperheads, cottonmouths/water moccasins) envenomation. See literature.
Adults and Children:
Administer as soon as possible after snakebite at first signs of envenomation (within 6 hours of bite). Give by IV infusion over 60 minutes. First 10 minutes, proceed slowly at 25–50mL/hr rate; monitor for any allergic reaction. If no reaction occurs, increase to 250mL/hr rate until complete. Initially: 4–6 vials. Observe up to 1 hour after completion of 1st dose; if no response, repeat additional dose of 4–6 vials until initial control achieved. After initially controlled, give additional 2-vial doses every 6 hours up to 18 hours (3 doses). May give additional 2-vial doses if necessary based on patient's clinical course.
History of papaya or papain allergy.
Coagulation defects (eg, cancer, collagen disease, CHF, diarrhea, elevated body temp, hepatic disorders, hyperthyroidism, poor nutritional state, steatorrhea, Vit. K deficiency). Monitor for signs/symptoms of recurrent coagulopathy for ≥1week; reevaluate for retreatment and consider using an anticoagulant or antiplatelet drug. Allergies to papain, chymopapain, papaya extracts, pineapple enzyme (bromelain), dust mites or latex allergens. Risk of anaphylactic reaction (esp. if allergic to sheep protein). Monitor for signs/symptoms of allergic reaction; discontinue if occurs. Have epinephrine, antihistamine and/or albuterol available. Developing fetuses and young children. Pregnancy (Cat.C). Nursing mothers.
Antivenin (monovalent immunoglobulin G [IgG] fragments).
Urticaria, rash, pruritus, nausea, back pain; coagulation abnormalities, anaphylactic reactions, delayed allergic reactions, serum sickness, others.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|